FDA labels AbbVie hep C drug Breakthrough

Share this article:

Abbvie and partner Enanta Pharmaceuticals have tucked a Breakthrough Therapy label under their belts. The FDA granted the expedited review status Friday to the experimental hepatitis C treatment that includes protease inhibitor ABT-450 and ombitasvir and dasabuvir, with or without the interferon ribavirin.

The all-oral's progress means the FDA will review the drug within six months, and that AbbVie deposited an additional milestone payment into Enanta's accounts.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.